Whole-brain activation signatures of weight-lowering drugs
نویسندگان
چکیده
منابع مشابه
Classification of Whole Brain fMRI Activation
Functional magnetic resonance imaging (fMRI) is an imaging technology which is primarily used to perform brain activation studies by measuring neural activity in the brain. It is an interesting question whether patterns of activity in the brain as measured by fMRI can be used to predict the cognitive state of a subject. Researchers successfully employed a discriminative approach by training cla...
متن کاملClassification of Whole Brain fMRI Activation Patterns
Functional magnetic resonance imaging (fMRI) is an imaging technology which is primarily used to perform brain activation studies by measuring neural activity in the brain. It is an interesting question whether patterns of activity in the brain as measured by fMRI can be used to predict the cognitive state of a subject. Researchers successfully employed a discriminative approach by training cla...
متن کاملLipid lowering drugs.
likelv that L donovani was of animal origin, as were other members of the genus, and in Brazil, foxes are a significant animal reservoir. The sensitivity of the Brazilian disease to antimonial drugs does not fit with the resistance of the infantum subspecies found in Portugal. Today there are epidemics of kala-azar among poor children in favelas in cities of north eastern Brazil such as Teresin...
متن کاملImpact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
Type 2 diabetes is a progressive disease, and most people with diabetes will eventually require adjunctive pharmacotherapy to optimize their glycemic control. As the majority of people with type 2 diabetes are overweight or obese, weight management is an essential component of diabetes management to improve their overall health and quality of life. Many of the currently available glucose-loweri...
متن کاملNew Era of Lipid-Lowering Drugs.
There are several established lipid-modifying agents, including statins, fibrates, niacin, and ezetimibe, that have been shown in randomized clinical outcome trials to reduce the risk of having an atherosclerotic cardiovascular event. However, in many people, the risk of having an event remains unacceptably high despite treatment with these established agents. This has stimulated the search for...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular Metabolism
سال: 2021
ISSN: 2212-8778
DOI: 10.1016/j.molmet.2021.101171